Stock MGRX MANGOCEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Mangoceuticals, Inc.

Equities

MGRX

US56270V1061

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
0.43 USD +11.46% Intraday chart for Mangoceuticals, Inc. +32.31% +55.29%
05:12pm Mangoceuticals Secures DEA Approval For HIPAA-Compliant Operating System via Surescripts MT
02:20pm MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mangoceuticals Secures DEA Approval For HIPAA-Compliant Operating System via Surescripts
MT
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
CI
Mangoceuticals Forms Partnership to Expand into Asia Pacific, Latin America; Shares Rise
MT
Mangoceuticals Patent Approved for Preventive Care in Australia
MT
Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
CI
Mangorx to Introduce ?Mojo? Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances
CI
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Gainers
MT
Mangoceuticals, Inc. to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
CI
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma
MT
Top Premarket Gainers
MT
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.
CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.
CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.
CI
Mangoceuticals, Inc. Officially Launches ?PRIME? by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment
CI
Mangoceuticals, Inc. Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
CI
Mangoceuticals, Inc. Accepting Pre Orders for its PRIME
CI
Mangoceuticals, Inc. to Introduce ?Prime?, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy Product
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MGRX Stock
  4. News Mangoceuticals, Inc.
  5. Highlights